Joshua Brumm

Genetic Medicines Biotech Dyne Pulls In $345M for Clinical Tests of Muscle Drugs

Dyne Therapeutics recently reported encouraging Phase 1/2 clinical data in myotonic dystrophy type 1 and Duchenne muscular dystrophy. At the J.P. Morgan Healthcare Conference, CEO Joshua Brumm said Dyne’s existing cash combined with the new capital is expected to last through 2025—well beyond the next key milestones for both therapeutic candidates.

By Frank Vinluan

Payers

At ViVE 2024, Panelists Share Prior Authorization Progress and Frustration in Payer Insights Program

At the Payer Insights sessions on Day 1 of ViVE 2024, a panel on prior authorization offered compelling insights from speakers who shared the positive developments in this area after years of mounting frustration. Speakers also shared challenges as they work with providers to figure out how policy developments and technology will work in practice.

Unlocking Transparency in PBM Pricing

The TSX Venture Exchange has a strong history of helping early-stage health and life sciences companies raise patient capital for research and development.